Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 6.54M | 7.83M | 6.36M | 4.91M | 4.81M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 12.74M | 13.33M | 13.70M | 12.00M | 12.55M |
Operating Income | -12.74M | -13.33M | -13.70M | -12.00M | -12.55M |
Income Before Tax | -2.29M | -14.66M | -919.40K | -26.64M | -7.94M |
Income Tax Expenses | 66.00K | -- | -- | -- | -60.00K |
Earnings from Continuing Operations | -2.36M | -14.66M | -919.40K | -26.64M | -7.88M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -2.36M | -14.66M | -919.40K | -26.64M | -7.88M |
EBIT | -12.74M | -13.33M | -13.70M | -12.00M | -12.55M |
EBITDA | -12.68M | -13.26M | -13.64M | -11.91M | -12.48M |
EPS Basic | -0.06 | -0.37 | -0.03 | -0.91 | -0.52 |
Normalized Basic EPS | -0.03 | -0.23 | -0.02 | -0.57 | -0.33 |
EPS Diluted | -0.06 | -0.40 | -0.18 | -0.91 | -0.53 |
Normalized Diluted EPS | -0.03 | -0.23 | -0.02 | -0.57 | -0.33 |
Average Basic Shares Outstanding | 41.94M | 39.34M | 35.82M | 29.35M | 15.05M |
Average Diluted Shares Outstanding | 41.94M | 39.79M | 37.45M | 29.35M | 15.05M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |